Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

434 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Guselkumab in patients with moderately to severely active ulcerative colitis (QUASAR): phase 3 double-blind, randomised, placebo-controlled induction and maintenance studies.
Rubin DT, Allegretti JR, Panés J, Shipitofsky N, Yarandi SS, Huang KG, Germinaro M, Wilson R, Zhang H, Johanns J, Feagan BG, Hisamatsu T, Lichtenstein GR, Bressler B, Peyrin-Biroulet L, Sands BE, Dignass A; QUASAR Study Group. Rubin DT, et al. Among authors: sands be. Lancet. 2024 Dec 17:S0140-6736(24)01927-5. doi: 10.1016/S0140-6736(24)01927-5. Online ahead of print. Lancet. 2024. PMID: 39706209
Acute Severe Ulcerative Colitis: An International Delphi Consensus on Clinical Trial Design and Endpoints.
Honap S, Jairath V, Sands BE, Dulai PS, Higgins PD, De Cruz P, Gutiérrez A, Kotze PG, Ye BD, Kobayashi T, Gearry RB, Olivera PA, Amiot A, Mosli MH, Al Awadhi S, Halfvarson J, Patel KV, Sebastian S, Danese S, Peyrin-Biroulet L. Honap S, et al. Among authors: sands be. Clin Gastroenterol Hepatol. 2024 Dec 14:S1542-3565(24)01082-6. doi: 10.1016/j.cgh.2024.10.029. Online ahead of print. Clin Gastroenterol Hepatol. 2024. PMID: 39681225 Free article.
Efficacy and safety of mirikizumab in patients with moderately-to-severely active Crohn's disease: a phase 3, multicentre, randomised, double-blind, placebo-controlled and active-controlled, treat-through study.
Ferrante M, D'Haens G, Jairath V, Danese S, Chen M, Ghosh S, Hisamatsu T, Kierkus J, Siegmund B, Bragg SM, Crandall W, Durand F, Hon E, Lin Z, Lopes MU, Morris N, Protic M, Carlier H, Sands BE; VIVID Study Group. Ferrante M, et al. Among authors: sands be. Lancet. 2024 Dec 14;404(10470):2423-2436. doi: 10.1016/S0140-6736(24)01762-8. Epub 2024 Nov 21. Lancet. 2024. PMID: 39581202 Clinical Trial.
Nuclear EGFR in breast cancer suppresses NK cell recruitment and cytotoxicity.
Escoto A, Hecksel R, Parkinson C, Crane S, Atwell B, King S, Ortiz Chavez D, Jannuzi A, Sands B, Bitler BG, Fehniger TA, Paek AL, Padi M, Schroeder J. Escoto A, et al. Among authors: sands b. Oncogene. 2024 Nov 9. doi: 10.1038/s41388-024-03211-0. Online ahead of print. Oncogene. 2024. PMID: 39521886
Three-Year Efficacy and Safety of Mirikizumab Following 152 Weeks of Continuous Treatment for Ulcerative Colitis: Results From the LUCENT-3 Open-Label Extension Study.
Sands BE, D'Haens G, Clemow DB, Irving PM, Johns JT, Gibble TH, Abreu MT, Lee SD, Hisamatsu T, Kobayashi T, Dubinsky MC, Vermeire S, Siegel CA, Peyrin-Biroulet L, Moses RE, Milata J, Panaccione R, Dignass A. Sands BE, et al. Inflamm Bowel Dis. 2024 Oct 25:izae253. doi: 10.1093/ibd/izae253. Online ahead of print. Inflamm Bowel Dis. 2024. PMID: 39448057
Clinical Trial Design Considerations for Hospitalised Patients With Ulcerative Colitis Flares and Application to Study Hyperbaric Oxygen Therapy in the NIDDK HBOT-UC Consortium.
Dulai PS, Bonner LB, Sadler C, Raffals LE, Kochhar G, Lindholm P, Buckey JC Jr, Toups GN, Rosas L, Narula N, Jairath V, Honap S, Peyrin-Biroulet L, Sands BE, Hanauer SB, Scholtens DM, Siegel CA; HBOT‐UC Consortium Investigators. Dulai PS, et al. Among authors: sands be. Aliment Pharmacol Ther. 2024 Dec;60(11-12):1512-1524. doi: 10.1111/apt.18326. Epub 2024 Oct 15. Aliment Pharmacol Ther. 2024. PMID: 39403018 Free PMC article. Review.
Assessment of outcomes in Crohn's disease: A systematic review of randomized clinical trials to inform a multiple outcome framework.
Moreira PL, Dignass A, Estevinho MM, Portal F, Mendes J, Santiago M, Reinisch W, Sands BE, D'Haens G, Mantzaris GJ, Danese S, Peyrin-Biroulet L, Jairath V, Dotan I, Magro F; International Organization for the Study of Inflammatory Bowel Diseases (IOIBD). Moreira PL, et al. Among authors: sands be. United European Gastroenterol J. 2024 Nov;12(9):1280-1291. doi: 10.1002/ueg2.12679. Epub 2024 Oct 11. United European Gastroenterol J. 2024. PMID: 39391955 Free PMC article. Review.
434 results